Piprazon 4.5 Injection is a robust antibiotic combination of Piperacillin (4000mg) and Tazobactam (500mg). This formulation is highly effective in treating a wide range of severe bacterial infections, including those caused by resistant strains.
Piperacillin is a broad-spectrum penicillin antibiotic that inhibits bacterial cell wall synthesis, leading to the destruction of the bacteria. Tazobactam, a beta-lactamase inhibitor, protects Piperacillin from enzymatic degradation by beta-lactamase-producing bacteria. Together, this combination extends the spectrum of antibacterial activity to cover Gram-positive, Gram-negative, and anaerobic bacteria, making it suitable for treating complex infections.
This medication is primarily indicated for the management of hospital-acquired pneumonia, complicated intra-abdominal infections, bloodstream infections (sepsis), complicated urinary tract infections, and skin and soft tissue infections. It is also frequently used as empirical therapy for critically ill patients due to its broad coverage.
Administered via intravenous infusion, Piprazon 4.5 Injection ensures rapid delivery and effectiveness. Its use is typically restricted to healthcare settings where patients can be closely monitored for therapeutic response and any adverse reactions.